HA-1077, Dihydrochloride (Fasudil)
|
C14H17N3O2S • 2HCl
|
364.30
|
PKA
|
Watanabe K. (2007) Nature Biotechnology 25 681
|
Swärd K. (2000) J. Physiol. 522 33
|
HA-1100 (Hydroxyfasudil)
|
C14H17N3O3S.HCl
|
343.83
|
ROCK
|
S. Wolfrum (2004) Arterioscler. Thromb. Vasc. Biol. 24 1842
|
|
Harmaline
|
C13H14N2O
|
214.26
|
serotonin, monoamine oxidase
|
Herraiz T. (2013) Drug Test. 1002/dta.1530.
|
|
Harmalol
|
C12H12N2O • HCl • 2H2O
|
272.73
|
serotonin, monoamine oxidase
|
Riba J. (2012) Drug Test. 610-6.
|
|
Harmane
|
C12H10N2
|
182.22
|
serotonin, monoamine oxidase
|
Smith KL. (2013) J Psychopharmacol. 162-70
|
|
Harmine
|
C13H12N2O
|
212.25
|
serotonin, monoamine oxidase
|
Song Y. (2004) Biochem. Biophys. Res. Commun. 317 128–132
|
|
HG-10-102-01
|
|
|
LRRK2
|
Choi H.G. (2012) ACS Med. Chem. Lett.
|
|
HG-9-91-01
|
C32H38ClN7O3
|
604.14
|
SIK
|
Clark K. (2012) Proc Natl Acad Sci USA 109(42) 16986-91
|
|
Hypothemycin
|
C19H22O8
|
378.37
|
cyclin D1
|
H. Sonoda (1999) Life Sci. 65 381
|
A. Zhao (1999) J. Antibiot. 52 1086
|
Ibrutinib
|
C25H24N6O2
|
440.50
|
BTK
|
|
|
IC261
|
C18H17NO4
|
311.30
|
CK1
|
Behrend L. (2000) Oncogene 19 5303
|
Mashhoon N. (2000) J. Biol. Chem. 275 20052
|
Icotinib
|
C22H21N3O4
|
391.40
|
EGFR
|
|
|
Idelalisib
|
C22H18FN7O
|
415.40
|
PI3K δ
|
|
|
IKK Inhibitor VII
|
C28H29N5OS
|
483.60
|
IKK
|
Waelchli R. (2006) Bioorg. Med. Chem. Lett. 16 108
|
|
IKK-2 Inhibitor IV (TPCA-1)
|
C12H10FN3O2S
|
279.30
|
IKK2
|
Podolin P.L. (2005) J. Pharmacol. Exp. Ther. 312 373
|
Karin M. (2004) Nat. Rev. Drug Discov. 3 17
|
IKK-2 Inhibitor VIII
|
C21H24N4O2
|
364.40
|
IKK2
|
Murata T. (2004) Bioorg. Med. Chem. Lett. 14 4019
|
|
IKK-3 inhibitor IX
|
C22H19N3O5S2
|
469.50
|
IKK3
|
Bamborough P. (2006) Bioorg. Med. Chem. Lett. 16 6236
|
|
Imatinib
|
C29H31N7O
|
493.60
|
BCR-ABL, c-KIT, PDGFR
|
Druker B. J. (2000) J. Clin. Invest. 105 3-7
|
|
IMD-0354
|
C15H8ClF6NO2
|
383.67
|
IKK2
|
Tanaka A, (2005) Blood 105 2324-2331
|
|
Infigratinib
|
C26H31Cl2N7O3
|
560.50
|
FGFR1-3
|
|
|